Dr Jan Ramaekers (J.G.)

Pronovost-Morgan, C., Greenway, K. T., Roseman, L., Williams, K., Wells, H., Tzarfaty, K., Timmermann, C., Lévesque, J. T., Tadwalkar, S., Szigeti, B., Shutte, T., Schneider, L., Sanders, J. W., Ruffell, S., Rucker, J., Roullier, I., Rochester, J., Risby, S., Richards, W., ... ReSPCT Experts (2025). An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-025-03685-9

Reckweg, J. T., Mason, N. L., Theunissen, E. L., Svendsen, C. B., Terwey, T. H., & Ramaekers, J. G. (2025). Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT. Frontiers in Psychology, 16, Article 1543640. https://doi.org/10.3389/fpsyg.2025.1543640

Prevete, E., Theunissen, E. L., Kuypers, K. P. C., Paci, R., Reckweg, J. T., Cavarra, M., Toennes, S. W., Ritscher, S., Bersani, G., Corazza, O., Pasquini, M., & Ramaekers, J. G. (2025). An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans. Psychopharmacology, 242(6), 1363-1376. https://doi.org/10.1007/s00213-024-06734-2

Ramaekers, J. G., Reckweg, J. T., Mason, N. L., Kuypers, K. P. C., Toennes, S. W., & Theunissen, E. L. (2025). Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study. Neuropsychopharmacology, 50(7), 1084-1092. https://doi.org/10.1038/s41386-024-02042-7

Ramaekers, J. G. (2025). Less is more? Antidepressant effects of short-acting psychedelics. Neuropsychopharmacology, 50(6), 875-876. https://doi.org/10.1038/s41386-025-02103-5

Ramaekers, J. G., Reckweg, J. T., Mason, N. L., Kuypers, K. P. C., Toennes, S. W., & Theunissen, E. L. (2025). Low to moderate doses of 3-methylmethcathinone (3-MMC) produce analgesic effects in healthy volunteers: a proof of principle study with a designer drug. Psychopharmacology. Advance online publication. https://doi.org/10.1007/s00213-025-06798-8

Madrid-Gambin, F., Haro, N., Mason, N. L., Mallaroni, P., Theunissen, E. L., Toennes, S. W., Pozo, O. J., & Ramaekers, J. G. (2025). Metabolomic profiling of cannabis use and cannabis intoxication in humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 50(6), 920-927. Article 104433. https://doi.org/10.1038/s41386-025-02082-7

Uthaug, M. V., Allocca, G., Havenith, M., Szabo, A., Rosas, F., & Ramaekers, J. G. (2025). Exploring the importance of bodyset for the psychedelic experience and beyond. Journal of Psychedelic Studies. https://doi.org/10.1556/2054.2025.00418

Timmermann, C., Sanders, J. W., Reydellet, D., Barba, T., Luan, L. X., Angona, Ó. S., Ona, G., Allocca, G., Smith, C. H., Daily, Z. G., Mason, N. L., Kloft-Heller, L., Kuchar, M., Janeckova, L., Palenicek, T., Erritzoe, D., Ramaekers, J. G., Carhart-Harris, R. L., & Uthaug, M. V. (2025). Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness. Neuroscience of Consciousness, 2025(1), Article niaf007. https://doi.org/10.1093/nc/niaf007

Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025). Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry? International Review of Neurobiology, 231-268. https://doi.org/10.1016/bs.irn.2025.03.002